Analysis of Post-Colonoscopy Colorectal Cancer and Its Subtypes in a Screening Programme by Unanue Arza, Saloa et al.
cancers
Article
Analysis of Post-Colonoscopy Colorectal Cancer and Its
Subtypes in a Screening Programme
Saloa Unanue-Arza 1,2,* , Isabel Idigoras-Rubio 3,4, Maria Jose Fernández-Landa 5, Isabel Bilbao-Iturribarria 3,





M.J.; Bilbao-Iturribarria, I.; Bujanda,
L.; Portillo, I. Analysis of
Post-Colonoscopy Colorectal Cancer
and Its Subtypes in a Screening
Programme. Cancers 2021, 13, 5105.
https://doi.org/10.3390/cancers
13205105
Academic Editor: Stephen P. Pereira
Received: 22 September 2021
Accepted: 9 October 2021
Published: 12 October 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Nursing I, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU),
48940 Leioa, Spain
2 Biocruces Health Research Institute, Clinical Nursing and Community Health, 48903 Barakaldo, Spain




4 Biocruces Health Research Institute, Cancer Biomarker Area, 48903 Barakaldo, Spain
5 Osakidetza Basque Health Service, OSI Bilbao-Basurto, Rekalde Ambulatory, 48002 Bilbao, Spain;
mariajose.fernandezlanda@osakidetza.eus
6 Biodonostia Health Research Institute, 20014 San Sebastian, Spain;
LUIS.BUJANDAFERNANDEZDEPIEROLA@osakidetza.eus
7 Center for Biomedical Research Network for Liver and Digestive Diseases (CIBERehd),
20014 San Sebastian, Spain
8 Department of Gastroenterology, Donostia University Hospital, Faculty of Medicine and Nursing,
University of the Basque Country (UPV/EHU), 20014 San Sebastian, Spain
* Correspondence: saloa.unanue@ehu.eus
Simple Summary: This study responds to the algorithm proposed by the World Endoscopy Orga-
nization (WEO) and adapts well to the surveillance of the adverse effects of the population-based
colorectal cancer (CRC) screening programmes (interval cancers). In our case, the application of the
aforementioned algorithm to the Basque Country Programme, which began in 2009 and reached
coverage of around 100% in 2014, has been an opportunity to evaluate in a standardised way the
cancers detected after a colonoscopy carried out following a positive Faecal Immunochemical Test
(FIT). All the characteristics found in these cancers and their relationship with the index colonoscopy
have been described. The differences in both the stage and the quality of the colonoscopies and the
lesions detected must be taken into consideration, in order to evaluate the surveillance and to reduce
one of the adverse effects on a CRC screening programme, as far as possible.
Abstract: Using the algorithm of the World Endoscopy Organisation (WEO), we have studied
retrospectively all colorectal cancers, both detected and non-detected by the Basque Country screening
programme from 2009 to 2017. In the screening programme 61,335 colonoscopies were performed
following a positive Faecal Immunochemical test (FIT) (≥20 µg Hb/g faeces) and the 128 cases of
post-colonoscopy colorectal cancer (PCCRC) detected were analysed. Among them, 50 interval type
PCCRCs were diagnosed (before the recommended surveillance), 0.8 cases per 1000 colonoscopies
performed, and 78 non-interval type PCCRCs (in the surveillance carried out at the recommended
time or delayed), 1.3 per 1000 colonoscopies. Among the non-interval type PCCRCs, 61 cases
were detected in the surveillance carried out at the recommended time (type A) and 17 when the
surveillance was delayed (type B), 1 case per 1000 colonoscopies performed and 0.28 cases per 1000
colonoscopies performed, respectively. Interval type PCCRC is less frequent than non-interval type
PCCRC. In interval type PCCRCs, CRCs detected in advanced stages (stages III–IV) were significantly
more frequent than those detected in early stages, compared to those of non-interval type PCCRCs
(OR = 3.057; 95% CI, 1.410–6.625; p < 0.005). Non-interval type B PCCRCs are less frequent than
non-interval type A PCCRCs, but the frequency of advanced stages is higher in interval type B
PCCRCs.
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1. Introduction
The Colorectal Cancer (CRC) Screening Programmes have the objective of reducing
the incidence and mortality linked to this cause. The screening test chosen by the majority
of European Union (EU) countries is the Faecal Immunochemical Test (FIT).
Although the FIT has proven its effectiveness [1,2], and colonoscopy is the Gold
standard for the detection of CRC and premalignant lesions [3], not all CRCs of the
population participating in the screening are detected within the prevention programme
and are thus considered false negatives. This is one of the adverse effects of screening
programmes, referred to as Interval Cancer (IC). According to the definitions proposed by
the group of experts of the World Endoscopy Organization (WEO), there are two specific
entities that have historically been categorised as CRC not detected by the programmes:
(a) FIT Interval Cancers (FIT-IC), defined as CRCs diagnosed between two invitations, after
a negative FIT result and before the next invitation; (b) post-colonoscopy colorectal cancers
(PCCRC). These are divided into interval type PCCRCs, where the cancer is identified
before the next recommended surveillance examination, and non-interval type PCCRCs,
where CRC is diagnosed at or after the recommended surveillance interval. Likewise,
another subdivision analyses non-interval type PCCRCs according to the moment of
diagnosis, type A (detected at recommended surveillance interval), type B (detected after
recommended surveillance interval) and type C (detected when no surveillance interval
has been set) [4].
The study of these entities allows us to evaluate both the diagnostic capacity of the
screening test, as well as the quality of the colonoscopies carried out after both a positive
result in the FIT and in the surveillance.
For this reason, and following international recommendations, it is essential to count
on a consensus of definitions and indicators, which will allow us to evaluate and com-
pare results with other programmes [5–7]. In order to do so, we have taken into account
the recommendations of the European Guidelines for Quality Assurance in Colorectal
Cancer Screening and Diagnosis [8,9], as well as those adopted by The Spanish Cancer
Screening Network [10]. The endoscopic findings of the screening colonoscopy have
these surveillance recommendations: (1) Normal or Hyperplasic Polyps-invitation to CRC
screening programme with FIT in 10 years; (2) Low Risk: 1 or 2 adenomas <10 mm
and without a villous component—invitation to CRC screening programme with FIT
in 5 years; (3) Intermediate Risk: 3 to 5 adenomas and/or 10 to 19 mm and/or villous
component—surveillance colonoscopy in 3 years; (4) High Risk: ≥5 adenomas and/or
≥20 mm—surveillance colonoscopy recommended within one year. In 2014, new defini-
tions were agreed upon by the Expert Working Group on interval CRC of the Colorectal
Cancer Screening Committee of the World Endoscopy Organization (WEO), which we have
taken into consideration in our study, in order to classify the detected and non-detected
lesions by the Basque Country programme, following the strategy aimed at improving its
effectiveness.
The assessment of the quality criteria for the colonoscopy [11], such as the adenoma
detection rate by the endoscopist, caecal intubation rate and quality of colonic cleansing
by endoscopist are necessary parameters in order to measure, assess and possibly predict
the rate of PCCRC and above all, represents an important quality indicator [12–15]. The
detailed study of each case will enable the implementation of correction measures in screen-
ing and surveillance colonoscopies. Moreover, taking into account the sociodemographic,
comorbidity and deprivation index [16,17] will allow the adjustment of results for future
intervention in the screening and surveillance.
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This study is the continuation of the one published before [18], including a wider
period of surveillance, allowing us to use the proposed classification by the WEO in the
case of PCCRCs.
The main objective is to evaluate the CRC cases detected by the Basque Country
programme between January 2009 and December 2017, specifically those of the Post-
Colonoscopy Colorectal Cancers in order to know about their common and differential
characteristics so as to improve the CRC screening process and surveillance.
2. Materials and Methods
2.1. Study Design and Study Population
A retrospective observational study of CRCs detected through the Basque Country
screening programme since the programme started, from 1 January 2009 to 31 December
2017 in individuals born between 1 January 1940 and 31 December 1967, was carried
out. Women and men of 50 to 69 years old, living in the Basque Country (one of the
17 autonomous regions in Spain) and subject to screening (611,000 people) were invited by
means of a biennial quantitative faecal immunochemical test (FIT) with a threshold ≥20 µg
Hb/g OC-Sensor® Micro (Eiken Chemical Co., Ltd., Tokyo, Japan).
2.2. Data Sources
All detected and non-detected cases by the CRC screening programme are monitored
following by the coordination centre following the Clinical Practice Guidelines. We con-
sidered CRC the codes 1530–1548 of the International Classification of Illnesses-9 [19] in
primary and secondary diagnosis IC-DO-10 (C18–C20) [20]. All cases ≥pT1 were consid-
ered CRC, coded according to the criteria of the American Joint Committee on Cancer
(AJCC) [21].
The following sources were used for the study:
• Database of the Basque country’s CRC screening programme;
• Basque Country Mortality Registry (completed up to 2020);
• Basque Country Cancer Registry (completed up to 2017);
• Discharges from the Standardised Virtual Medical Registries (Osabide) of the Basque
Health System—Osakidetza (completed up to 2020).
Selection of cases:
• Screen-detected CRC: CRCs detected within the screening programme after a positive
FIT;
• FIT-IC: CRCs diagnosed between two invitations, after a negative FIT result and before
the next invitation and followed 2 years after the last negative test (70–71-years-old);
• FIT positive without colonoscopy performed after six months and CRC detected;
• Post-imaging CRC: CRCs detected after an imaging procedure and reported as normal;
• Interval type PCCRC: CRCs detected before the next recommended surveillance
interval;
• Non-interval type PCCRC: CRCs detected at or after recommended surveillance
interval:
◦ Non-interval type A PCCRC: CRCs detected at recommended surveillance inter-
val;
◦ Non-interval type B PCCRC: CRCs detected after recommended surveillance
interval;
◦ Non-interval type C PCCRC: CRCs detected when no surveillance interval has
been set.
In all cases, colonoscopies were analysed according to the quality criteria proposed
by the Clinical Practice Guidelines for quality in colonoscopy screening and colorectal
cancer of the AEG-SEED: caecal intubation, colonic cleansing according to the Boston scale
(adequate quality considered to be a score of ≥6 with a minimum score of 2 in each of
the three sections of the colon), location and characteristics of the previous polypectomy
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(type of resection: piecemeal or bloc, grade of dysplasia and morphology of the resected
adenoma in the screening colonoscopy according to the Paris classification). Moreover,
the characteristics of the tumour were described, such as the stage and the degree of
differentiation (according to the WEO Consensus Statements).
The deprivation index was included, assigned to each patient according to the census
tract in five quintiles, from very low (high socioeconomic status) to high (the lowest
socioeconomic status) [22].
2.3. Main Outcome Measures
The main result was the possibility of obtaining the characteristics of PCCRCs accord-
ing to the classification proposed by the Interval Cancer Experts Group. The non-interval
type C PCCRC was not studied since no cases without surveillance recommendation were
registered.
2.4. Statistical Analysis
Continuous variables were described by mean and standard deviation. The categorical
variables were described by frequencies and percentages. Comparisons between categorical
variables were performed using the chi-square test or Fisher’s test when the expected
frequencies were less than 5. The confidence intervals were calculated at a 95% confidence
level, and all results were considered statistically significant for p < 0.05.
A logistical regression analysis was carried out with the significant variables in order
to estimate the Odds Ratios with a confidence interval of 95%. Values p < 0.05 were
considered statistically significant.
Non-parametric tests were carried out for the analysis of the time elapsed between
the performance of the index colonoscopy and the diagnosis of CRC: Mann-Whitney U
test for the contrast between the periods of interval type PCCRCs and non-interval type
PCCRCs, and Kruskal-Wallis for the analysis of the differences between groups, in relation
to the different findings in each of the PCCRCs (the latter depends on the importance of
including the analysis of both interval and non-interval types).
The incidence is shown as the number of cases per 1000 person-years, along with
the confidence interval at 95%. In order to do so, in each case we used the corresponding
number of cases detected after the index colonoscopy (Figure 1), and the median of the
surveillance period for each patient according to the group they belonged to, interval type
PCCRC and non-interval type PCCRC (non-interval type A PCCRC, non-interval type B
PCCRC).
Correlations between variables have not been considered. The analysis was carried
out by a biomedical statistician using the statistical programs SPSS 23.0, IBM (Armonk, NY,
USA) and R, version 4.0.1.
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Figure 1. Findings in the colonoscopies carried out, and corresponding recommended surveillance according to the
European Guideline for Quality Assurance in Colorectal Cancer Screening and Diagnosis and the consensus of the Spanish
Cancer Screening Network [9,23].
3. Results
3.1. Study Population
There were 1,636,530 invitations registered in the studied period. The overall partici-
pation rate was 69.7%, being higher in women than in men (73.76% vs. 68.86%; OR = 1.27;
95% CI, 1.236 to 1.280; p = 0.000). With regards to age, both in men and in women, par-
ticipation was significantly higher in the group of 60–69-year-olds than in the group of
50–59-year-olds (p = 0.000).
The negative FIT cases (<20 µg Hb/g faeces) were 1,074,307 (94.2%). The positivity
rate was higher in men than in women (7.3% vs. 4.4%; OR = 1.679; 95% CI, 1.670 to 1.724;
p = 0.000). With regards to age, in men positivity was lower in the group of 50–59-year-olds
than in the 60–69-year-old group. (6.1% vs. 8.8%; OR = 0.681; 95% CI, 0.667 to 0.696;
p = 0.000). In women, positivity was lower in the 50–59-year-old group than in the 60–
79-year-old group (3.9% vs. 6.4%; OR = 0.745; 95% CI, 0.727 to 0.764; p = 0.000). 93.1%
underwent a screening colonoscopy (61,335) with a definitive diagnostic and surveillance
guidelines according to the detected risk. Figure 1 shows the findings in the colonoscopies
carried out and the recommended surveillance for each of them.
Figure 2 shows all the CRCs detected in the analysed period according to the classifica-
tion of the WEO group of experts are shown in Figure 2. The CRCs detected in the private
health system (16 cases) were included for the total count, in addition to those specified in
the figure, but excluded from the analysis.
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All the findings 0.116 (0.088–0.153) 0.160 (0.129–0.200) 0.128 (0.010–0.165) 0.030 (0.019–0.049)
No lesion 0.122 (0.078–0.190) 0.011 (0.003–0.041) - 0.010 (0.003–0.036)
Inflammatory Bowel Disease - 0.339 (0.093–1.228) 0.173 (0.030–0.975) 0.147 (0.026–0.828)
Low-Risk Adenoma 0.235 (0.148–0.371) 0.080 (0.039–0.166) 0.047 (0.018–0.121) 0.030 (0.010–0.088)
Intermediate-Risk Adenoma 0.117 (0.065–0.209) 0.094 (0.051–0.173) 0.077 (0.039–0.152) 0.016 (0.004–0.059)
High-Risk Adenoma 0.027 (0.007–0.098) 0.662 (0.510–0.859) 0.580 (0.438–0.768) 0.082 (0.041–0.162)
Inconclusive - 0.525 (0.093–2.928) - 0.456 (0.081–2.540)
3.2. Patient and Tumour Characteristics of PCCRC Cases
Table 2 shows the sociodemographic and tumour related characteristics, of the PCCRC
divided into (a) Interval type PCCRC and (b) Non-interval type PCCRC. There were no
statistically significant differences except for tumour stage, 54% of the interval type PCCRC
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and 78.2% of the non-interval type PCCRCs were found in an early stage (p = 0.004).
Advanced stage PCCRCs are three times more likely to be interval type PCCRCs than
non-interval type PCCRCs (OR = 3.057; 95% CI, 1.410 to 6.625; p = 0.05). In relation to the
period of time elapsed (months) between the performance of the index colonoscopy and
the diagnosis of CRC, we observed that, in the cases in which a low-risk adenoma or an
intermediate-risk adenoma is detected, there are statistically significant differences. On the
other hand, in relation to interval type PCCRCs, the cases in which a low-risk adenoma
has been detected, the period of time elapsed until the detection of CRC is statistically
significantly higher than when an intermediate-risk adenoma or a high-risk adenoma is
detected (p = 0.009).








OR 1 CI p-Value
Sex (n (%))
Men 27 (54) 53 (67.9) - - -
Women 23 (46) 25 (32.1) - - -
Age group (n (%))
Mean (SD) 62.78 (5.4) 65.24 (5.05) - - -
50–59 years 13 (26) 10 (12.8) - - -
60–69 years 30 (60) 52 (66.7) - - -
≥70 years 7 (14) 16 (20.5) - - -
Tumour location (n (%))
Caecum 8 (16) 11 (14.1) - - -
Proximal 14 (28) 28 (35.9) - - -
Distal 19 (38) 29 (37.2) - - -
Rectum 9 (18) 10 (12.8) - - -
Tumour stage (n (%))
Early stage (I–II) (Ref.) 27 (54) 61 (78.2) - - -
Advanced stage (III–IV) 23 (46) 17 (21.8) 3.057 1.410–6.625 0.005
Deprivation index (n (%))
Q1 (Very low) (less deprived) 7 (14) 11 (14.1) - - -
Q2 (Low) 6 (12) 15 (19.2) - - -
Q3 (Moderate) 12 (24) 15 (19.2) - - -
Q4 (High) 12 (24) 17 (21.8) - - -
Q5 (Very high) (most deprived) 11 (22) 19 (24.4) - - -
Unknown 2 (4) 1 (1.3) - - -
Time between the index colonoscopy and




36 - - 0.314
No lesion 36.74(17.773)34
52.50 (24.749)
52.5 - - 0.286
Inflammatory Bowel Disease - 42.5 (40.305)42.5 - - -
Low-risk adenoma 33.83(20.171)33.0
64.43 (8.344)
68.0 - - 0.000
Intermediate-risk adenoma 17.64 (8.310)18
38.80 (5.029)
37.5 - - 0.000
High-risk adenoma 22.50 (2.121)22.5
30.95 (22.418)
20 - - 0.915
1 ORs were only calculated for variables that had a significance p < 0.05 in the univariate analysis. Abbreviations: SD, standard deviation.
Table 3 describes the characteristics of colonoscopies in which PCCRC was later
detected, both interval type PCCRC and non-interval type PCCRC, according to the
colonoscopy quality criteria and lesions detected in the index colonoscopy. No statis-
tically significant differences were found in terms of quality, but differences were found
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in terms of resection and findings detected in index colonoscopy. In the group of non-
interval type PCCRC, 71.8% were classified as high-risk adenoma in the index colonoscopy.
However, in the interval type PCCRC, 38% showed no adenomatous lesion and 36% had
low-risk adenoma in the index colonoscopy. In terms of the type of polyp according to
the Paris classification, 58.3% of the interval type PCCRCs were sessile (Is), whereas 39.6%
of the non-interval type PCCRCs were pedunculated (Ip). No statistically significant dif-
ferences were found in terms of location of the tumour. With regard to the location of the
tumour in relation to the finding in index colonoscopy, it coincided in 76.0% of the interval
type PCCRCs. In 32.1% of the non-interval type PCCRCs the tumour did not coincide
with the location of the detected and resected lesion (OR = 6.713; 95% CI, 3.003 to 15.009;
p = 0.000).









OR 1 CI p-Value
Caecal intubation (n (%))
Complete 50 (100) 76 (97.4) - - -
Incomplete 0 (0.0) 1 (1.3) - - -
Non-applicable 0 (0.0) 1 (1.3) - - -
Boston Bowel Preparation Scale (n (%))
Adequate ≥6 41 (82.0) 56 (71.8) - - -
Poor <6 2 (4.0) 10 (12.8) - - -
Non-applicable 7 (14.0) 12 (15.4) - - -
Endoscopic finding (n (%)) 2
No lesion 19 (38.0) 2 (2.6)
133.00 22.533–785.013 0.000Inflammatory Bowel Disease 0 (0.0) 2 (2.6)
Low-risk adenoma 18 (36.0) 7 (9.0) 72.00 13.707–378.205 0.000
Intermediate-risk adenoma 11 (22.0) 10 (12.8) 30.80 5.915–160.385 0.000
High-risk adenoma (Ref.) 2 (4.0) 56 (71.8) - - -
Inconclusive 0 (0.0) 1 (1.2) - - -
Coincident location (n (%)) 3
Yes (Ref.) 12 (24.0) 53 (67.9) - - -
No 38 (76.0) 25 (32.1) 6.713 3.003–15.009 0.000
Location of adenoma resected (n (%))
Caecum 1 (8.3) 5 (9.4) - - -
Proximal colon 5 (41.7) 17 (32.1) - - -
Distal colon 4 (33.3) 27 (50.9) - - -
Rectum 2 (16.7) 4 (7.5) - - -
Paris Classification (n (%))
Is (Ref.) 7 (58.3) 13 (24.5) - - -
Isp 1 (8.3) 5 (9.4) 0.371 0.036–3.838 0.406
Ip 1 (8.3) 21 (39.6) 0.088 0.010–0.803 0.031
IIa/IIb 1 (8.3) 14 (26.4) 0.133 0.014–1.230 0.075
Unknown 2 (16.7) 0 (0.0) - - -
Adenoma retrieved (n (%))
Yes 9 (44.4) 50 (94.3) - - -
No 3 (25.0) 3 (5.7) - - -
1 ORs were only calculated for variables that had a significance p < 0.05 in the univariate analysis. 2 In the calculation of the Odds Ratio, the
categories “no lesion” and “inflammatory bowel disease” were unified. 3 Location of the CRC coincident with the location of the previously
resected adenoma.
In Table 4 the comparative analysis between non-interval type A and type B PCCRCs
is shown. No statistically significant differences were found in any of the variables related
to the sociodemographic characteristics or the tumour characteristics. However, despite the
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delay in performing the colonoscopy of surveillance in the non-interval type B PCCRC cases
as opposed to those performed following the recommendation and risk of non-interval
type A PCCRC, no significant differences were found in the stage of the tumour, even
though the percentage of CRCs in advanced stages was higher in the non-interval type B
PCCRC. Regarding the characteristics and findings of the index colonoscopy, statistically
significant differences were found in quality of colonic cleansing at index colonoscopy as
shown in Table 5, in fact, poor colonic cleansing (lower than 6 in the Boston scale) was
more frequent in non-interval type B PCCRCs in relation to non-interval type A PCCRCs
(35.3% vs. 3.3%). Moreover, the percentage of high-risk adenoma was significantly higher
in non-interval type A PCCRCs.
Table 4. Characteristics of non-interval type A PCCRC and non-interval type B PCCRC.
Variables 1
Non-Interval Type A PCCRC
(n = 61)
Non-Interval Type B PCCRC
(n = 17)
Sex
Men 44 (72.1) 9 (52.9)
Women 17 (27.9) 8 (47.1)
Age group (n (%))
Mean (SD) 64.87 (4.836) 66.59 (5.702)
50–59 years 8 (13.1) 2 (11.8)
60–69 years 42 (68.9) 10 (58.8)
≥70 years 11 (18.0) 5 (29.4)
Deprivation index (n (%))
Q1 (Very low) 11 (18.0) 0 (0.0)
Q2 (Low) 11 (18.0) 4 (23.5)
Q3 (Moderate) 12 (19.7) 3 (17.6)
Q4 (High) 12 (19.7) 5 (29.4)
Q5 (Very high) 15 (24.6) 4 (23.5)
Unknown 0 (0.0) 1 (5.9)
Topography (n (%))
Caecum 10 (16.4) 1 (5.9)
roximal 21 (34.4) 7 (41.2)
Distal 23 (37.7) 6 (35.3)
Rectum 7 (11.5) 3 (17.6)
Tumour stage (n (%))
Early stage (I–II) 50 (82.0) 11 (64.7)
Advanced stage (III–IV) 11 (18.0) 6 (35.3)
1 ORs were not calculated due to the fact that none of the variables had a significance p < 0.05 in the univariate
analysis.








OR 1 CI p-Value
Caecal intubation (n (%))
Complete 60 (98.4) 16 (94.1) - - -
Incomplete 0 (0.0) 1 (5.9) - - -
Non-applicable 1 (1.6) 0 (0.0) - - -
Boston Bowel Preparation Scale (n (%))
Adequate ≥6 45 (73.8) 10 (58.8) 13.5 2.368–76.978 0.003
Poor <6 (Ref.) 2 (3.3) 6 (35.3) - - -
Non-applicable 14 (23.0) 1 (5.9) - - -









OR 1 CI p-Value
Endoscopic finding (n (%)) 2
No lesion (Ref.) 0 (0.0) 2 (11.8) - - -
Inflammatory Bowel Disease (Ref.) 1 (4.6) 1 (5.9) - - -
Low-risk adenoma 4 (5.1) 3 (17.6) 4.00 0.265–60.325 0.317
Intermediate-risk adenoma 8 (13.1) 2 (11.8) 12.00 0.773–186.362 0.076
High-risk adenoma 48 (78.7) 8 (47.1) 18.00 1.660–195.215 0.017
Inconclusive 0 (0.0) 1 (5.9) - - -
Coincident location (n (%)) 3
Yes 45 (73.8) 8 (47.1) 3.164 1.043–9.602 0.042
No (Ref.) 16 (26.2) 9 (52.9) - - -
Location of adenoma resected (n (%))
Caecum 1 (5.9) 10 (16.4) - - -
Proximal colon 7 (41.2) 21 (34.4) - - -
Distal colon 6 (35.3) 23 (37.7) - - -
Rectum 3 (17.6) 7 (11.5) - - -
Paris Classification (n (%))
Is (Ref.) 12 (19.7) 1 (5.9) - - -
Isp 2 (3.3) 3 (17.6) 0.056 0.004–0.838 0.037
Ip 20 (32.8) 1 (5.9) 1.667 0.095–29.182 0.727
IIa/IIb 11 (18.0) 3 (17.6) 0.306 0.028–3.390 0.334
CRC no coincident with the previously resected 16 (26.2) 9 (52.9) - - -
Adenoma retrieved (n (%))
Yes 42 (68.9) 8 (47.1) - - -
No 4 (6.6) 0 (0.0) - - -
Not applicable 15 (19.2) 9 (11.5) - - -
1 ORs were only calculated for variables that had a significance p < 0.05 in the univariate analysis. 2 In the calculation of the Odds Ratio, the
categories “no lesion” and “inflammatory bowel disease” were unified. 3 Location of the CRC coincident with the location of the previously
resected adenoma.
4. Discussion
In this study, both the detected and non-detected CRCs by the CRC screening pro-
gramme were classified according to the WEO proposal, specifically analysing the interval
and non-interval PCCRC types in the Basque Country between 2009 and 2017 [4]. This
monitoring has been possible due to the availability of both cancer and hospital discharge
registries, which despite their limitations provide us with a good monitoring tool for the
adverse effects of screening programmes [24].
Like in the study carried out by Mlakar et al. in 2018 in Slovenia [25] our results did
not show statistically significant differences either according to age, sex, location of the
tumour or deprivation index among the two types of PCCRC detected. With regard to the
location of the CRC, the results of our study differ from those of Dossa et al. due to the
fact that although a higher frequency of CRC in distal colon was observed (38% and 37.2%)
in both interval type and non-interval type PCCRCs in our study, they observed that the
majority of cases were located in the proximal colon (54.2% of 367 PCCRCs) [26]. However,
it should be noted that these studies included persons with symptoms with previous
pathologies such as inflammatory bowel disease, hereditary syndromes, previous CRC,
polyposis or diverticulosis. In the case of the Basque Country, these were not considered,
as the participants in the screening programme were average risk, asymptomatic people of
50 to 69 years old. The recent article by Beaton et al. (2021) found that 48 of the 527 cases
studied were PCCRCs, of which 7 (15%) were interval type PCCRCs and 41 (85%) non-
interval type PCCRCs. In our study, they were 50 (39.1%) and 78 (60.9%) respectively,
although it should be noted that in Beaton’s study, the percentage of the CRCs detected in
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screening programmes was 8% of all cases analysed [27]. Likewise, the importance that
these authors give to the adherence to the surveillance in order to avoid the numerous
cases of non-interval type PCCRC is ratified by the results of our study. The percentage of
non-interval type PCCRCs (78/128 cases) was lower than that reported in their study due
to the fact that the protocol of the screening programme in the Basque Country includes
the recommendation of surveillance for all colonoscopies and compliance is monitored.
In our study PCCRCs were mostly detected in their early stages (I and II), in fact, the
probability of detecting a tumour in an advanced stage in the interval type PCCRCs is three
times higher than in non-interval type PCCRCs. Our results are similar to those of the
study by Anderson et al. and Willington et al. in which 63.6% of the 107 PCCRCs analysed
and 63% of 46 PCCRCs analysed were diagnosed in the early stages, respectively [28,29].
Regarding PCCRCs on the whole, however, the fact that in these studies there is no
differentiation between interval type PCCRC and non-interval type PCCRC does not allow
us to contrast our results following the proposed classification.
The interval type PCCRCs could correspond to new, rapidly evolving lesions or to
undetected lesions in the colonoscopy screening, due to the fact that 76% were detected in a
different location to the adenoma resected in the index colonoscopy. In studies published in
this regard, the results differ from ours. On one hand, Robertson et al., in 2014, concluded
that the undetected lesions in the colonoscopy were responsible for 50–60% of the interval
cancers and Zhao et al., in 2019, carried out a meta-analysis in which they concluded a
rate of 26% missed adenomas [30,31]. This would indicate that these lesions not detected
in the index colonoscopy could progress towards an invasive cancer and be detected as
interval or non-interval type PCCRC, depending on the date of diagnosis. On the other
hand, Hsu et al., in 2021, observed that 68.8% of interval type PCCRCs developed from a
new lesion [32]. Likewise, Jennings et al. observed that 47% of the interval type PCCRCs
detected in a programme in which guaiac faecal occult blood test is used as the screening
test were related to non-detected lesions, being 27% likely new CRCs and 20% were related
to missed detection [33]. In our study, adenomas were removed in 31 of the colonoscopies
that were later interval type PCCRCs (62%) and in 73 of the 78 CRCs classified as non-
interval type PCCRCs (93.6%). Despite this, the programme registers parameters of quality
in accordance with the recommendations of the ESGE [34], including caecal intubation,
colonic cleansing and adenoma and CRC detection rate (23.9 and 3.4 respectively per 1000
participants) [35]. This could be related to the low percentage of interval type PCCRCs that
have been identified in this study. The results are in accordance with those found by Nally
et al., who, in their study published in 2019, found that a low adenoma detection rate was
directly linked to the detection of interval cancers [36]. On the other hand, in the study by
Farrar et al., in 2006, a relationship was found between incomplete polypectomy and the
detection of interval cancer [37].
With regards to non-interval type PCCRCs, 71% of CRCs were found in the colonoscopy
for the surveillance of high-risk adenomas detected in the index colonoscopy. The location
of the CRC coincided with the previously resected lesion (67.9%) although 78.2% were
found in an early stage. This would indicate the appropriateness of the surveillance of these
cases being carried out within 1 year [13] while questioning the proposed surveillance after
3 years of the index colonoscopy, except in sessile lesions ≥20 mm resected in piecemeal
(6 months) [38]. Even though these new recommendations will allow us to reduce the
burden on healthcare of the follow-up colonoscopies, it will be essential to monitor all the
cases thoroughly due to the fact that in our study 20 non-interval type PCCRCs would
have been considered interval type.
On the other hand, differences were found with regards to the morphology of the
lesions retrieved during index colonoscopy, 58.3% were sessile (Paris Is) in the interval type
PCCRCs and 39.6% pedunculated (Paris Ip) in the non-interval type PCCRCs. Accordingly,
Yamaguchi et al., in 2020, observed that the type of lesion and the retrieved lesions that
had not been retrieved for pathological study were related to a higher risk of PCCRC [39].
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This was not observed in our study due to the fact that the programme does not assign a
risk until the complete resection of the lesions, be it in one or in several sessions.
Another result that should be highlighted in this study is the possibility of establishing
and comparing the adherence to the surveillance colonoscopies of the non-interval type
A and type B PCCRCs. Accordingly, 61 people with CRC diagnosis had it carried out in
the recommended period and 17 at a later date. The quality of the colonic cleansing was
13.5 times worse in the non-interval type B PCCRC ones than in those of non-interval type
A PCCRC. There were no statistically significant differences in the stage of the tumour.
This would indicate that a delay in undergoing a surveillance colonoscopy does not have
serious consequences, although a larger sample would be needed to confirm it. Moreover,
the fact that all colonoscopies are subsequently followed up is a quality criterion that
is based on the protocol of the programme, whereby the Endoscopy Unit carries out an
informed recommendation once the colonoscopy and pathological anatomy reports have
been assessed and it is filed in the clinical history.
Nevertheless, even though it is essential to keep monitoring all cases, due to the size
of our sample and the surveillance period, the consensus proposal of the group of experts
on interval cancer of the WEO [40] is of great value in order to compare the quality of the
CRC screening programmes and to improve the processes and surveillance, taking the
index colonoscopy as the starting point.
Moreover, a limitation of this study is that the sample is small once disaggregated
into the different subtypes according to the classification proposed by the experts in IC. It
would be very interesting to continue studying the cases over a length of time in order to
increase the sample size.
The usage of data from different programmes and regions will improve the sample size
and, with the study of the different categories of PCCRC, the surveillance recommendations
may even vary, which is why we encourage its use and comparison in the near future
owing to the fact that available evidence is still scarce.
5. Conclusions
The classification of the WEO experts in interval cancer provides a common framework
to monitor and compare the surveillance and results of screening programmes.
Interval type PCCRCs and non-interval type PCCRCs show differences in terms of the
characteristics of the lesion detected in the index colonoscopy, its location and morphology.
The probability of finding advanced stages in the case of interval type PCCRCs is three
times higher than in non-interval type PCCRCs.
The risk of interval type PCCRC is higher in the cases in which low-risk or intermediate-
risk adenomas were found, whilst in the case of non-interval type PCCRCs, the risk is
higher with high-risk adenomas.
In the non-interval type PCCRCs, no significant differences were found, in relation
to the stage of the tumour, between those whose colonoscopy was performed in the
recommended time frame (type A) and those whose colonoscopy was delayed (type B).
The proposed classification tool is useful and manageable. Furthermore, it clearly
reflects the different entities within the subgroups, thus allowing us to see areas of im-
provement in the surveillance of the lesions, which will allow us to decrease those cases of
interval type PCCRCs with worse prognosis.
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